Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP

Seven Eight Capital LP lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 245.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,876 shares of the biotechnology company’s stock after buying an additional 11,279 shares during the period. Seven Eight Capital LP’s holdings in Ascendis Pharma A/S were worth $2,165,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ASND. Vestal Point Capital LP purchased a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $78,719,000. GSA Capital Partners LLP purchased a new stake in Ascendis Pharma A/S in the 1st quarter worth approximately $992,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $5,779,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $16,648,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday. Citigroup lifted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday. Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They set a “buy” rating and a $200.00 target price on the stock. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Finally, Jefferies Financial Group boosted their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $193.77.

Ascendis Pharma A/S Stock Performance

ASND opened at $148.88 on Thursday. The company has a 50-day moving average of $132.71 and a 200-day moving average of $136.43. The company has a market capitalization of $8.67 billion, a P/E ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.